Gemcitabine arterial infusion chemotherapy versus intravenous chemotherapy for patients with advanced pancreatic cancer: a comparative study
10.3760/cma.j.issn.1674-1935.2009.01.005
- VernacularTitle:吉西他滨动脉灌注化疗与外周静脉化疗治疗中晚期胰腺癌的比较研究
- Author:
Lin JIA
;
Jianjun ZHENG
;
Shineng ZHANG
;
Derong XIE
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Drug therapy;
Gemcitabine;
Transarterial infusion
- From:
Chinese Journal of Pancreatology
2009;9(1):15-17
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy of gemcitabine arterial infusion chemotherapy with intravenous chemotherapy in the management of patients with advanced pancreatic cancer and to evaluate the efficacy and safety of gemcitabine arterial infusion chemotherapy. Methods 43 patients with advanced pancreatic cancer were included in this study, of whom 21 patients received arterial infusion chemotherapy (Group A) and the other 22 were treated by intravenous chemotherapy (Group B), gemcitabine combined with 5-FU chemotherapy was administrated in both groups. The main outcomes were clinical benefit response (CBR), tumor response rate and toxicity. Results Compared with Group B, there was a significant improvement of CBR in group A (81% vs 50%, P =0.033) ; there was also significant improvement of pain control in group A (76.2% vs 45.5%, P =0.039). There was no significant difference in the tumor response rate between two groups (33.3% vs 22.7%, P =0.498). No significant increase of side effects was observed in both groups. Conclusions In the management of advanced pancreatic cancer, the arterial infusion method may be more favorable than intravenous approach in improving clinical benefits with mild toxicity and well tolerability.
